Introduction
============

Coffee is the second most consumed beverage after water and its main constituent, caffeine, is the most widely consumed drug, improving attention and alertness, and normalizing mood and cognition ([@B30]; [@B69]). These central effects of caffeine result from the antagonism of adenosine receptors ([@B30]), in particular A~1~ receptors (A~1~R) and A~2A~ receptors (A~2A~R), which are the main adenosine receptors in the brain ([@B31]). Because of its hydrophobic properties, brain concentrations of caffeine are similar to plasma concentrations ([@B50]; [@B30]), in the range of 20--70 μM upon moderate intake ([@B74]; [@B39]; [@B11]). These concentrations trigger the maximal psychostimulant effects of caffeine ([@B6]). Careful consideration of caffeine concentration is important since most effects of caffeine are bell-shaped, being a psychostimulant with neuroprotective actions at moderate doses and a depressant with deleterious effects at higher doses ([@B62]; [@B69]; [@B20]).

Moderate doses of caffeine antagonize adenosine receptors ([@B16]; [@B24]; [@B40]; [@B38]; [@B79]; [@B67]), whereas higher caffeine concentrations act on other targets such as the inhibition of phosphodiesterases, the modification of GABA~A~ receptor function or the release of calcium from intracellular calcium stores ([@B46]; [@B51]; [@B30]; [@B4]). These are likely associated with the toxic effects of caffeine ([@B80]). Since A~1~R are inhibitory, reducing excitatory synaptic transmission and neuronal excitability ([@B22]), whereas A~2A~R are mostly excitatory, facilitating synaptic plasticity processes ([@B12]), it is assumed that the neurostimulant effect of caffeine mostly results from the partial antagonism of A~1~R whereas the neuroprotective effects of caffeine may results from limiting excessive A~2A~R activation ([@B29]; [@B12]). The role of A~1~R in the cerebral cortex has mostly been studied in rodents, where A~1~R are mostly located at synapses ([@B73]; [@B59]), in particular at excitatory rather than at inhibitory synapses (e.g., [@B63]). At excitatory synapses, A~1~R depress synaptic transmission and neuronal excitability through a combined presynaptic action decreasing glutamate release, post-synaptic actions decreasing the activation of glutamate receptors and voltage-sensitive calcium channels ([@B17]; [@B43]) as well as extra-synaptic actions through a decrease of neuronal excitability by controlling potassium rectifier channels ([@B35]), after-hyperpolarization potentials ([@B37]) and HCN ([@B45]). Both *in vivo* and *in vitro* studies in rodents concluded that the inhibitory effect of A~1~R predominantly results from the presynaptic inhibition of glutamate release ([@B56]; [@B75]).

Despite the clear effects of caffeine in human subjects on cortical regions resulting in alterations of vigilance, mood, and cognition ([@B69]; [@B20]), the functional impact of caffeine on neuronal excitability and information flow in the human cerebral cortex is not yet characterized. On a molecular level, moderate doses of caffeine affect A~1~R binding ([@B5]) and occupancy in human cortical neurons ([@B25]; [@B55]). While studies in rodents revealed an ability of caffeine to partially antagonize some A~1~R-mediated effects ([@B56]; [@B58]), responses in the human cortical network might differ as A~1~R have clear inter-species differences, typified by a lower density ([@B5]; [@B19]; [@B27]; [@B70]), a higher affinity for agonists and a lower affinity for antagonists in human *versus* rodent cerebral cortex ([@B53]; [@B28]; [@B47]). Therefore, we here delineate the synaptic and subsynaptic localization of A~1~R in the human cerebral cortex, and test how A~1~R affect neuronal excitability and excitatory synaptic transmission. We report how caffeine at realistic concentrations reached in the brain parenchyma and experienced by coffee consumers after 1--2 cups of coffee, affects these neuronal and synaptic A~1~R actions in human neocortex.

Materials and Methods {#s1}
=====================

Human Samples
-------------

All procedures on human brain resection material that had to be removed for the surgical treatment of deeper brain structures were performed with the approval of the Medical Ethical Committee of the VU University Medical Centre, written informed consent by patients involved, and in accordance with Dutch license procedures and the declaration of Helsinki, as previously described ([@B77]). Human brain samples were also collected at autopsies, performed at the Instituto Nacional de Medicina Legal e Ciências Forenses, which approved all procedures according to the rules of the European Consortium of Nervous Tissues: BrainNet Europe II, to protect the identity of individual donors, as previously described ([@B57]).

Membrane Preparation and Binding Assays
---------------------------------------

Total membranes and synaptic membranes (from a synaptosomal preparation) were obtained by isopicnic and gradient centrifugations of homogenized brain tissue, as previously described ([@B60]; [@B57]). To determine the enrichment and basic binding characteristics of A~1~R in cortical synapses, we compared saturation binding isotherms of the selective A~1~R antagonist ^3^H-DPCPX (0.1--10 nM; specific activity of 102.1 Ci/mmol; from DuPont NEN) in total and synaptosomal membranes (72--164 μg) incubated for 2 h incubation at room temperature in a buffer containing 50 mM Tris, 1 mM EDTA, 2 mM EGTA, pH 7.4, with adenosine deaminase (4 U/ml, Roche) before filtration through Whatman GF/C filters (Millipore), as previously described ([@B59]; [@B10]). To estimate the binding affinity of caffeine, we carried out displacement curves of ^3^H-DPCPX binding with caffeine (0.1--300 μM; from Sigma), as previously described ([@B10]). Results are expressed as specific binding, determined by subtraction of the non-specific binding, which was measured in the presence of 2 μM 8-{4-\[(2-aminoethyl)amino\]carbonylmethyloxyphenyl}xanthine (XAC, a mixed A~1~R/A~2A~R antagonist; from Tocris) and normalized per amount of protein (bicinchoninic acid assay). To derive the binding parameters from saturation curves (K~D~ and B~max~ values) the data were fitted by a rectangular hyperbola using the GraphPad Prism software. For displacement binding curves, IC~50~ values were converted to K~i~ values by non-linear fitting of the semi-logarithmic curves derived from the competitions curves.

Subsynaptic Fractionation and Western Blot Analysis
---------------------------------------------------

To separate the extrasynaptic (non-active) zone, presynaptic active zone and post-synaptic fractions from synaptosomes, we used a fractionation method previously described in detail ([@B60]; [@B7]). The efficiency of separation is based on the segregation of different markers in the several fractions: SNAP-25 in the presynaptic active zone, PSD-95 in the post-synaptic density and synaptophysin outside the active zone (extrasynaptic fraction). Western blot analysis was performed with a rabbit anti-A~1~R antibody (1:500, Thermo Scientific), as previously described ([@B59]).

Human Brain Slice Preparation and Electrophysiological Recordings
-----------------------------------------------------------------

Human brain slices were derived from resected tissue obtained from patients suffering from mild-to severe forms of epilepsy (*n* = 6, of which 5 were diagnosed with meso-temporal epilepsia, 1 with dysplasia; average age 44.8 ± 10.0). All obtained tissue is derived from the temporal lobe area (*n* = 6), away from the focal area of the epilepsy. Slices were prepared as described previously ([@B72]; [@B77]). Briefly, blocks of resected cortical tissue were transported to the laboratory in carbogen-saturated (95% O~2~, 5% CO~2~ at pH 7.4) ice-cold choline-based slicing solution containing (in mM): 110 choline chloride, 11.6 sodium ascorbate, 2.5 KCl, 1.3 NaH~2~PO~4~, 7 MgCl~2~, 0.5 CaCl~2~, 26 NaHCO~3~, 10 glucose. Cortical slices (350--400 μm) were prepared in the same ice-cold solution as used for transport, and then transferred to holding chambers with artificial cerebrospinal fluid (aCSF) containing (in mM) 125 NaCl, 3 KCl, 1.25 NaH~2~PO~4~, 1 MgSO~4~, 2 CaCl~2~, 26 NaHCO~3~, 10 glucose. Here, they were stored for 30 min at 34°C and subsequently at room temperature for at least 1 h before recording.

Following recovery, recordings from cells in deeper layers of the human temporal cortex were made in oxygenated aCSF (flow rate of 2--3 ml/min, 32°C). Whole-cell patch-clamp recordings were made with borosilicate glass pipettes (3--6 MΩ) filled with an intracellular solution containing (in mM): 111 [K]{.smallcaps}-gluconate, 8 KCl, 10 HEPES, 4 Mg-ATP, 10 K~2~HPO~4~, 0.4 GTP, 0.2 EGTA. Biocytin (0.5%) was added to all solutions for *post hoc* cell identification, and osmolarity was adjusted to 290--295 mOsm. Pyramidal neurons were visualized with differential interference contrast microscopy, selected based on their large and pyramidal shape and further identified by their spike profile. During recordings, cells were kept at a holding potential close to -70 mV. Recordings were made using MultiClamp 700 A/B amplifiers (Axon Instruments, Sunnyvale, CA, United States), sampling at 10 kHz and low-pass filtering at 3--4 kHz. Recordings were digitized with an Axon Digidata 1440A and acquired using pClamp software (Axon). Acquired data were stored for off-line analysis.

To characterize the electrophysiological properties of pyramidal neurons, we used a step protocol to calculate the input resistance (Rin) as the slope of the linear fit through the current--voltage relationship in 10 pA steps. The membrane time constant was obtained by fitting a single exponential function to the membrane potential deflection in response to a -50 pA current injection. The sag was calculated as the percentage of the difference between transient and stable membrane potentials to a hyperpolarization amplitude of -10 mV after injecting a negative current. The rheobase was defined as the minimal current amplitude of 1 s duration that resulted in the first action potential (AP). Analysis of spike waveforms was performed on single APs elicited by depolarizing threshold current pulses. The AP half-width was defined as the spike width at its half amplitude. To study synaptic transmission, we evaluated spontaneous events that were detected using MiniAnalysis software. The average amplitude and frequency of excitatory post-synaptic potentials (EPSPs) was determined over a time span of 5 min.

The tested drugs, adenosine (20 μM, Sigma), caffeine (50 μM, Sigma) or DPCPX (100 nM, Tocris), were used in concentrations previously tested in rodent preparations ([@B14]; [@B65]; [@B11]) and were dissolved in aCSF at the desired concentration and bath applied during the experiments.

Morphological Analysis
----------------------

After recording, slices were fixed at 4°C for at least 24 h in 100 mM phosphate buffer saline containing 4% paraformaldehyde (pH 7.4), for subsequent neuronal visualization and reconstruction as previously described ([@B52]). Slices containing biocytin-filled neuronal pairs were processed using a protocol described previously ([@B52]). Slices were incubated in 0.1% Triton X-100 solution containing avidin biotinylated horseradish peroxidase (ABC-Elite; Camon); subsequently, they were reacted using 3,3-diaminobenzidine as a chromogen under visual control until the dendritic and axonal arborization was clearly visible (usually after 2--4 min). Slices were dehydrated and then mounted on slides, embedded in Mowiol and enclosed with a thin coverslip.

Biocytin-labeled neurons were examined under the light microscope. Representative pairs were photographed at low magnification to document the dendritic and axonal arborization. Subsequently, neurons were reconstructed with the aid of Neurolucida software (MicroBright Field).

Statistical Analysis
--------------------

Data are means ± SEM. Paired Student's *t*-test or Wilcoxon signed-rank test (*n* \< 10) was used for statistical comparisons between two groups and one-way ANOVA followed by *post hoc* Tukey's test for statistical comparisons among multiple groups. The normality of the distribution of values was determined by the Kolmogorov--Smirnov test. Statistical significance was set at *p* \< 0.05.

Results
=======

Synaptic Localization of A~1~R in the Human Cerebral Cortex
-----------------------------------------------------------

To define if A~1~R were enriched in synapses of the human cerebral cortex, as occurs in rodents ([@B73]; [@B59]), we compared the binding density of the previously validated selective A~1~R antagonist ^3^H-DPCPX ([@B70]) in membranes from synaptosomes (purified synapses) and in total membranes (mostly representing non-synaptic neuronal and astrocytic membranes) from human neocortical tissue. **Figure [1A](#F1){ref-type="fig"}** shows that the binding density of A~1~R was larger in synaptosomal membranes (B~max~ = 755 ± 22 fmol/mg protein, *n* = 5) than in total membranes (B~max~ = 421 ± 17 fmol/mg protein, *n* = 5; *p* \< 0.001 *versus* synaptosomal membranes; unpaired Student's *t*-test).

![A~1~R are enriched and evenly distributed in human cortical synapses, and have greater affinity for caffeine and selective A~1~R antagonist compared to extra-synaptic A~1~R. **(A)** The selective A~1~R antagonist ^3^H-DPCPX binds with greater affinity and to a larger number of A~1~R in synaptosomal compared to total membranes of the human temporal cortex. Data are mean ± SEM of five subjects. **(B)** Caffeine has a greater affinity to displace the binding of the selective A~1~R antagonist ^3^H-DPCPX (2 nM) from synaptosomal compared to total membranes of the human temporal cortex. Data are mean ± SEM of five subjects. **(C)** Western blots of subsynaptic fractions prepared from synaptosomes (SYN) showing the subsynaptic distribution of A~1~R in the human temporal cortex (*n* = 2). A~1~R are present in all the subsynaptic fractions, outside (EXTRA) and inside the presynaptic active zone (PRE) and post-synaptic density (POST).](fphar-08-00899-g001){#F1}

Interestingly, ^3^H-DPCPX displayed a higher affinity to bind A~1~R in synaptosomal membranes (K~D~ = 2.68 nM, 95% confidence interval: 2.12--3.24 nM, *n* = 5) than in total membranes (K~D~ = 4.58 nM, 95% confidence interval: 3.69--5.46 nM, *n* = 5; *p* = 0.0079 *versus* synaptosomal membranes; unpaired Student's *t*-test). These different binding properties of synaptic *versus* extra-synaptic A~1~R in the human cerebral cortex were confirmed by the different apparent affinity of caffeine for these two populations of A~1~R. In fact, competition curves of ^3^H-DPCPX binding by caffeine (a non-selective adenosine receptor antagonist; [@B16]) showed that caffeine displaced ^3^H-DPCPX binding with greater efficiency in synaptosomal membranes (K~i~ = 11.53 μM, 95% confidence interval: 7.89--15.17 μM, *n* = 5) than in total membranes (K~i~ = 33.02 μM, 95% confidence interval: 25.18--40.86 μM, *n* = 5; *p* = 0.0079 *versus* synaptosomal membranes; unpaired Student's *t*-test) (**Figure [1B](#F1){ref-type="fig"}**). This is suggestive of a possible difference in human cerebral cortical synaptic and extra-synaptic membranes of the homo- or heterodimerization of A~1~R, which has been shown to affect the binding of caffeine and A~1~R antagonists ([@B9]; [@B34]).

We further detailed the localization of A~1~R within human cerebral cortical synapses. Using different subsynaptic fractions prepared from synaptosomes of the human temporal cortex, we concluded that A~1~R are present in all the subsynaptic fractions on somatodendritic (post-synaptic) and axon terminal (presynaptic) compartments, inside and outside the presynaptic active zone and post-synaptic density (**Figure [1C](#F1){ref-type="fig"}** and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). Such a widespread distribution predicts a complex role for the A~1~R in the control of synaptic communication in the human cerebral cortex.

Adenosine Effects on Intrinsic Membrane Properties of Pyramidal Neurons Are Mediated by A~1~R
---------------------------------------------------------------------------------------------

Adenosine, at non-toxic concentrations (i.e., in low μM range), is known to affect intrinsic membrane properties of layers 2--3 and layer 5 pyramidal neurons in the rodent cerebral cortex through the activation of A~1~R ([@B56]; [@B76]). Since A~1~R activation also controls excitability in the human brain ([@B42]) by still undefined mechanisms, we first characterized the effect of exogenous adenosine application on membrane properties of pyramidal neurons in the human temporal cortex (**Figure [2A](#F2){ref-type="fig"}**). On average, adenosine (20--100 μM) did not decrease the resting membrane potential (RMP; control: -67.2 ± 2.3 mV; adenosine: -67.2 ± 3.4 mV; difference: 0.01 ± 3.7 mV, *n* = 12, paired *t*-test: *p* = 0.99), while it did lower the input resistance (R~input~; control: 45.9 ± 16.7 MΩ; adenosine: 40.4 ± 14.5 MΩ; difference: 5.5 ± 6.5 MΩ, *n* = 12, paired *t*-test: *p* = 0.01; **Figures [2C,F](#F2){ref-type="fig"}**) and increased the current injection needed before firing of the first AP, expressed as the rheobase value (Rheobase; control: 251.7 ± 130.5 pA; adenosine: 344.5 ± 149.9 pA; difference: 92.8 ± 45.0 pA, *n* = 12, paired *t*-test: *p* \< 0.0001; **Figures [2B,E](#F2){ref-type="fig"}**). Altogether these changes lead to a decreased neuronal excitability and a need for a larger input to fire an AP. Furthermore, adenosine decreased the voltage sag (Sag; control: 2.1 ± 1.2 mV; adenosine: 1.6 ± 1.1 mV; difference: 0.45 ± 0.44 mV, *n* = 12, paired *t*-test: *p* = 0.003; **Figures [2D,G](#F2){ref-type="fig"}**), reflecting an adenosine-induced partial block of HCN channels, as described in rodents ([@B45]). These effects of adenosine were not seen at 5 μM and were concentration-dependent in the range of 20--100 μM.

![A~1~R-mediated effects on intrinsic membrane properties are moderately affected by caffeine. **(A)** Biocytin reconstruction of deeper layer pyramidal neuron from slice of human temporal cortex showing dendritic (black) and axonal (gray) branches. ^∗^Axonal branches stretch longer than could be depicted here. **(B,E)** Rheobase value of pyramidal neurons increased after adenosine application (20--100 μM, green, **E**, left panel). This effect was blocked by pre-incubation of DPCPX (100 nM, red, **E**, middle panel), but still occurred when caffeine was pre-incubated (50 μM, blue, **E**, right panel). Paired *t*-test comparing adenosine (20--100 μM) to ACSF condition: ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.001. Boxes depict average ± SD. **(C,F)** Input resistance of pyramidal neurons decreased after adenosine application (20--100 μM, **F**, left panel). Both DPCPX (100 nM, red, **F**, middle panel) and caffeine (50 μM, **F**, blue, right panel) inhibited adenosine-induced effects (striped green). Paired *t*-test comparing adenosine (20--100 μM) to ACSF condition: ^∗^*p* \< 0.05. Boxes depict average ± SD. **(D,G)** The sag of hyperpolarization-activated cationic depolarizing current (I~h~) decreased after adenosine application (20--100 μM, **G**, left panel). Both DPCPX (100 nM, red, **G**, middle panel) and caffeine (50 μM, blue, **G**, right panel) inhibited adenosine-induced effects (striped green). Paired *t*-test comparing adenosine (20--100 μM) to ACSF condition: ^∗^*p* \< 0.05. Boxes depict average ± SD.](fphar-08-00899-g002){#F2}

The effects of adenosine on membrane intrinsic properties were due to A~1~R activation, since the selective A~1~R antagonist DPCPX (100 nM) blocked the effects of adenosine on the rheobase (DPCPX: 275.0 ± 125.5 pA; DPCPX+adenosine: 293.6 ± 120.4 pA; difference: 16.4 ± 25.0 pA, *n* = 7, paired *t*-test: *p* = 0.13; **Figures [2B,E](#F2){ref-type="fig"}**), input resistance (DPCPX: 42.2 ± 20.5 MΩ; DPCPX+adenosine: 33.0 ± 12.9 MΩ; difference: 2.2 ± 5.5 MΩ, *n* = 7, paired *t-*test: *p* = 0.33; **Figures [2C,F](#F2){ref-type="fig"}**), and sag (DPCPX: 2.3 ± 1.2 mV; DPCPX+adenosine: 2.5 ± 0.6 mV; difference: 0.1 ± 0.6 mV, *n* = 7, paired *t*-test: *p* = 0.72; **Figures [2D,G](#F2){ref-type="fig"}**). By itself, DPCPX (100 nM) did not significantly alter these membrane properties: rheobase (control: 350.0 ± 151.2 pA; DPCPX: 275.0 ± 125.5 pA; difference 75.0 ± 133.8 pA, *n* = 8, paired *t*-test: *p* = 0.16; **Figures [2B,E](#F2){ref-type="fig"}**), Input resistance (control: 44.4 ± 22.7 MΩ; DPCPX: 42.2 ± 20.5 MΩ; difference: 0.2 ± 5.8 MΩ, *n* = 8, paired *t-*test: *p* = 0.92; **Figures [2C,F](#F2){ref-type="fig"}**) or sag (control: 2.1 ± 0.7 mV; DPCPX: 2.3 ± 1.2 mV; difference: 0.3 ± 0.6 mV, *n* = 8, paired *t*-test: *p* = 0.17; **Figures [2D,G](#F2){ref-type="fig"}**). This indicates the lack of a constitutive effect of endogenous adenosine on the A~1~R controlling membrane intrinsic properties of pyramidal neurons in human cortical slices.

Caffeine Does Not Modify Intrinsic Membrane Properties of Pyramidal Neurons
---------------------------------------------------------------------------

As with DPCPX, there were no effects of caffeine (50 μM) by itself on intrinsic membrane properties of pyramidal neurons in human temporal-cortical slices. The rheobase (control: 192.9 ± 73.4 pA; caffeine: 196.4 ± 69.8 pA; difference 18.2 ± 72.9 pA, *n* = 11, paired *t*-test: *p* = 0.42; **Figures [2B,E](#F2){ref-type="fig"}**), input resistance (control: 67.5 ± 21.0 MΩ; caffeine: 68.2 ± 16.3 MΩ; difference: 4.1 ± 10.3 MΩ, *n* = 11, paired *t-*test: *p* = 0.21; **Figures [2C,F](#F2){ref-type="fig"}**) and sag were unaltered (control: 1.4 ± 0.7 mV; caffeine: 1.6 ± 0.8 mV; difference: 0.3 ± 0.6 mV, *n* = 11, paired *t*-test: *p* = 0.12; **Figures [2D,G](#F2){ref-type="fig"}**). Since the selective A~1~R antagonist DPCPX had no effect by itself and thereby ruled out constitutive activation of A~1~R in human cortical slices, the lack of a direct effect of caffeine on intrinsic membrane properties suggests that A~2A~R are also not constitutively altering intrinsic membrane properties in human pyramidal neurons *in vitro* (reviewed in [@B12]).

We next tested if concentrations of caffeine reached in the brain parenchyma by moderate coffee drinkers (50 μM) could effectively antagonize the A~1~R-mediated control of the intrinsic membrane properties of pyramidal neurons. The effect of exogenously applied adenosine on the rheobase was still observed in the presence of caffeine (50 μM). Thus, when adenosine (20 μM) was added in the presence of caffeine (50 μM), the rheobase increased significantly (control: 192.9 ± 73.4 pA; caffeine+adenosine: 318.2 ± 110.8 pA; difference: 116.4 ± 108.7 pA, *n* = 11, paired *t*-test: *p* = 0.005; **Figures [2B,E](#F2){ref-type="fig"}**). In contrast, caffeine partially blocked the effects of adenosine on the input resistance (control: 67.5 ± 21.0 MΩ; caffeine+adenosine: 55.8 ± 13.6 MΩ; difference: 4.1 ± 10.3 MΩ, *n* = 11, paired *t-*test: *p* = 0.21; **Figures [2C,F](#F2){ref-type="fig"}**) and voltage sag (control: 1.4 ± 0.7 mV; caffeine+adenosine: 1.3 ± 0.5 mV; difference: 0.3 ± 0.7 mV, *n* = 11, paired *t*-test: *p* = 0.12; **Figures [2D,G](#F2){ref-type="fig"}**). This indicates that caffeine concentrations experienced by coffee drinkers can interfere with effects of adenosine on the intrinsic membrane properties of pyramidal neurons in human neocortex.

Adenosine Controls Synaptic Transmission through A~1~R
------------------------------------------------------

The impact of caffeine on cerebral cortical-mediated behavioral responses may also result from its ability to control glutamatergic synaptic transmission, as observed in rodents ([@B56]; [@B75]; [@B11]; [@B58]). To evaluate the effect of caffeine on glutamatergic synaptic transmission in the human neocortex, we made whole-cell recordings of large deeper-layer pyramidal neurons of the human temporal cortex and recorded spontaneous excitatory transmission. Adenosine (20 μM) significantly decreased both the amplitude of excitatory events (control: 41.7 ± 10.6 pA; adenosine: 38.1 ± 6.6 pA; difference: 3.9 ± 4.9 pA, *n* = 10, paired *t*-test: *p* = 0.03, **Figures [3D,E](#F3){ref-type="fig"}**) as well as the frequency of excitatory events (control: 1.8 ± 1.6 Hz; adenosine: 0.6 ± 0.5 Hz; difference: 1.2 ± 1.4 Hz; *n* = 10, paired *t*-test: *p* = 0.02; **Figure [3A](#F3){ref-type="fig"}**). Both effects were reversible upon washout of adenosine (**Figure [3E](#F3){ref-type="fig"}**; EPSC amplitude: wash-out: 43.6 ± 12.2 pA; difference vs. adenosine: 5.8 ± 6.6 pA; *n* = 10, paired *t*-test: *p* = 0.02; EPSC frequency: wash-out: 2.8 ± 2.2 Hz; difference vs. adenosine: 2.1 ± 1.8 Hz; *n* = 9, paired *t*-test: *p* = 0.009). The effects of adenosine were mediated by A~1~R, since the selective A~1~R antagonist DPCPX (100 nM) blunted the effect of exogenously added adenosine (20 μM) on frequency (control: 2.0 ± 1.8 Hz; DPCPX+adenosine: 1.9 ± 1.2 Hz; difference: 0.1 ± 0.9 Hz; *n* = 6, paired *t*-test: *p* = 0.77; **Figure [3B](#F3){ref-type="fig"}**) and amplitude of excitatory post-synaptic events (control: 41.8 ± 12.9 pA; DPCPX+adenosine: 51.7 ± 30.0 pA; difference: 9.7 ± 17.2 pA, *n* = 7, paired *t*-test: *p* = 0.18; **Figure [3F](#F3){ref-type="fig"}**). DPCPX (100 nM) by itself increased the frequency (control: 2.0 ± 1.8 Hz; DPCPX: 3.0 ± 2.0 Hz; difference: 1.1 ± 0.6 Hz; *n* = 6, paired *t*-test: *p* = 0.01; **Figure [3B](#F3){ref-type="fig"}**) but not the amplitude of excitatory synaptic events (control: 41.8 ± 12.9 pA; DPCPX: 49.8 ± 24.9 pA; difference: 8.0 ± 13.0 pA, *n* = 8, paired *t*-test: *p* = 0.13; **Figure [3F](#F3){ref-type="fig"}**), which may suggest a constitutive activity of presynaptic A~1~R inhibiting synaptic release of glutamate.

![A~1~R-mediated effects of adenosine on synaptic transmission are post-synaptically blocked by caffeine. **(A)** Adenosine (20 μM, green) significantly decreased the frequency of excitatory events onto pyramidal neurons in a reversible manner. Paired *t*-test comparing adenosine (20 μM) to ACSF condition: ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01. Boxes depict average ± SD. **(B)** Direct application of DPCPX (100 nM, red) significantly increased the frequency of excitatory events and blocked adenosine-induced inhibition (green). Paired *t*-test comparing DPCPX (100 nM) to ACSF condition: ^∗^*p* \< 0.05. Boxes depict average ± SD. **(C)** Caffeine pre-incubation (50 μM, blue) did not affect the potency of adenosine (20 μM, green) to decrease the frequency of excitatory events onto pyramidal neurons. Wash-out of adenosine and caffeine restored the frequency of events. Paired *t*-test comparing adenosine (20 μM) to ACSF condition: ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01. Boxes depict average ± SD. **(D)** Example trace of the average effect of adenosine application onto the amplitude of excitatory events onto a pyramidal neuron. **(E--G)** Adenosine (20 μM, green) significantly decreased the amplitude of excitatory events onto pyramidal neurons in a reversible manner **(E)**. Pre-incubation with either DPCPX (100 nM, red, **F**) or caffeine (50 μM, blue, **G**) completely abolished this effect. Paired *t*-test comparing adenosine (20 μM) to ACSF control/wash-out condition: ^∗^*p* \< 0.05.](fphar-08-00899-g003){#F3}

We next investigated the effect of caffeine concentrations experienced by most coffee drinkers (50 μM) on synaptic transmission in the presence of adenosine. Caffeine (50 μM) blocked the effect of adenosine (20 μM) on the amplitude of spontaneous excitatory events which indicates a post-synaptic effect of caffeine (control: 38.9 ± 10.3 pA; caffeine+adenosine: 36.7 ± 11.5 pA; difference: 2.1 ± 8.9 pA, *n* = 9, paired *t*-test: *p* = 0.49; **Figure [3G](#F3){ref-type="fig"}**), but did not prevent the effect of adenosine on the frequency of spontaneous events (control: 1.1 ± 0.7 Hz; caffeine+adenosine: 0.2 ± 0.1 Hz; difference: 0.9 ± 0.7 Hz; *n* = 9, paired *t*-test: *p* = 0.007; **Figure [3C](#F3){ref-type="fig"}**). Similar to the adenosine-only group, effects of adenosine in the case of pre-incubated caffeine could be washed out (wash-out: 0.5 ± 0.4 pA; difference vs. adenosine: 0.3 ± 0.3 pA; *n* = 8, paired *t*-test: *p* = 0.04; **Figure [3C](#F3){ref-type="fig"}**). In contrast to DPCPX, caffeine (50 μM) by itself had no effect on spontaneous glutamatergic synaptic transmission. It did not modify the amplitude (control: 38.9 ± 10.3 pA; caffeine: 40.1 ± 12.9 pA; difference: 1.1 ± 0.6 pA, *n* = 9, paired *t*-test: *p* = 0.59; **Figure [3G](#F3){ref-type="fig"}**) or frequency of spontaneous excitatory post-synaptic events (control: 1.1 ± 0.7 Hz; caffeine: 0.6 ± 0.2 Hz; difference: 0.5 ± 0.7 Hz; *n* = 9, paired *t*-test: *p* = 0.06; **Figure [3C](#F3){ref-type="fig"}**). This may suggest that, in contrast to DPCPX, moderate concentrations of caffeine are not sufficient to interfere with constitutive activity of presynaptic A~1~R. Together, our findings show that caffeine concentrations experienced by coffee drinkers interfere with adenosine signaling when there is an additional adenosine load, allowing to restore excitatory synaptic transmission and pyramidal neuron excitability in the human neocortex.

Discussion
==========

In this study, we provide the first characterization of the impact of caffeine concentrations experienced by moderate coffee drinkers (50 μM) on neuronal excitability in pyramidal neurons and excitatory synapses of the human temporal cortex. Caffeine had a larger affinity for synaptic A~1~R compared to extra-synaptic A~1~R in the human temporal cortex, which contrasts with the affinity profile of caffeine in the rodent cortex; this difference probably results from a different molecular organization of A~1~R within human cortical synapses compared to rodent cortical synapses. Caffeine interfered with several of the inhibitory A~1~R-mediated effects of adenosine in the human cortex, similar to previous observations in the rodent brain. Caffeine blunted the effects of adenosine on intrinsic membrane properties and prevented the amplitude reduction of excitatory synaptic transmission through antagonistic actions at post-synaptic A~1~R.

A distinct interaction of caffeine with A~1~R in the human cerebral cortex compared with rodent cortex is in agreement with several previous studies describing differences of binding properties of brain A~1~R between humans and different animal models ([@B5]; [@B53]; [@B19]; [@B28]; [@B27]; [@B47]; [@B70]). Our results confirmed previous evidence that the binding density of A~1~R in the temporal cortex is lower in humans compared to mice or rats ([@B5]; [@B19]; [@B27]; [@B70]). We also confirmed previous evidence that human A~1~R display a different affinity for xanthine-based selective antagonists, which tend to have lower affinity in humans compared to rodents ([@B53]; [@B28]; [@B47]). Despite these different pharmacological properties, human A~1~R seem to exert an overall inhibitory effect in the cerebral cortex that is similar to that observed in rodents: in fact, the exogenous administration of adenosine decreased the excitability of pyramidal neurons in the human temporal cortex in a manner similar to the inhibition previously reported to occur through A~1~R activation in the cerebral cortex of rodents ([@B56]; [@B45]). In rodents ([@B75]), tonic adenosine inhibition is dominated by a A~1~R-mediated inhibition of excitatory transmission. In human neocortex, both intrinsic membrane properties of pyramidal neurons as well as excitatory synaptic transmission received by these neurons, were inhibited by somatodendritic post-synaptic A~1~R. Whether one of these mechanisms dominates effects of adenosine on cortical overall excitability in human neocortex cannot be concluded based on our present results. We did find a high density of A~1~R in human cortical synapses, both at somatodendritic (post-synaptic) and axon terminals (presynaptic) compartments, as well as a greater affinity for DPCPX of synaptic A~1~R in comparison with extra-synaptic A~1~R, which may point to a stronger control of synaptic transmission by A~1~R. Since one of the few factors that has been documented to regulate the affinity of A~1~R for antagonists is their relative homomerization ([@B34]) or heteromerization ([@B9]), the present findings are suggestive of a different molecular arrangement of A~1~R in synapses of the human cerebral cortex.

To characterize the impact of caffeine on human cortical neurons, we used a concentration of caffeine within the range of concentrations reached by caffeine in the brain parenchyma upon moderate consumption of caffeine (20--70 μM) ([@B74]; [@B39]; [@B11]; [@B21]; [@B66]), which are similar to plasma concentrations of caffeine that cause maximal psycho-activating responses in humans ([@B6]). Many studies have described neuronal effects of caffeine using high millimolar or submillimolar concentrations of caffeine ([@B44]; [@B49]; [@B48]; [@B78]; [@B36]), which represent toxic effects of caffeine found in extreme cases of caffeinism ([@B32]). Using concentrations of caffeine realistic for normal human consumption, we found that caffeine only targets inhibitory A~1~R, since caffeine mimics the effects of DPCPX. This is in agreement with PET imaging studies that documented a decreased occupancy of cortical A~1~R in subjects consuming caffeine ([@B25]; [@B55]). Importantly, we now report that caffeine displays a greater affinity for synaptic A~1~R compared to extra-synaptic A~1~R. This may suggest that synaptic A~1~R are more strongly affected by caffeine and that interference with inhibitory effects of adenosine on transmission at excitatory synapses is a major effect in the human cerebral cortex. In contrast to effects in rodent neocortex, we find that effects of caffeine in human cortical neurons interfered both with adenosine effects on neuronal excitability and excitatory synaptic transmission through post-synaptic A~1~R, while in rodents, caffeine mostly controls synaptic transmission through presynaptic A~1~R and affect the release of excitatory neurotransmitters ([@B56]; [@B35]). Nevertheless, also in rodent neocortex, caffeine can exert a post-synaptic effect ([@B35]; [@B68]) in accordance with the ability of post-synaptic A~1~R to induce robust responses in rodent cortical neurons ([@B76]; [@B58]). Differences in effects of caffeine in human and rodent neocortex may result from the previously discussed different molecular organization of A~1~R or to a different subsynaptic distribution of A~1~R in rodent and human cortical synapses; thus, A~1~R seem to be more abundant presynaptically in rodent synapses ([@B73]; [@B59]), whereas we find here in human neocortex an even distribution of A~1~R in all subsynaptic fractions.

For our experiments, we used neocortical tissue derived from epileptic patients that underwent surgery for treatment of deeper brain structures. Although the resected tissue was from regions outside the focal area of epilepsy or tumor, and was not part of the disease, our observations could be affected by disease and medication history. Earlier, adenosine A~1~R density was shown to be up- or downregulated in surrounding neocortical areas of patients suffering from temporal lobe epilepsy ([@B1]; [@B33]) and adenosine A~1~R agonists are explored as therapeutic targets to treat epilepsy ([@B2]). Therefore, the possibility that epileptic conditions affect the adenosine neuromodulation system in the cerebral cortex ([@B60]) should be considered as a factor influencing the presently reported effects of caffeine. However, the impact of caffeine in epileptic conditions is still largely unclear ([@B23]; [@B64]) and seems to be more evident in the developing than in the mature brain (e.g., [@B71]), with reports of proconvulsant (e.g., [@B8]) and anticonvulsant effects of caffeine (e.g., [@B61]). It is also important to keep in mind that the present study focused on the human temporal cortex and it remains to be confirmed if the effects of caffeine are similar in other cortical regions, although both the density of A~1~R and the occupancy of A~1~R by caffeine seem to be similar in different cortical areas ([@B70]; [@B18]; [@B25]; [@B54]).

The present characterization of the effects of a physiological concentration of caffeine (50 μM) on the human temporal cortex provides an important insight in the subtle effects of cortical exposure to human caffeine consumption. By acting mainly post-synaptically, caffeine is able to counteract adenosine-induced inhibition of the received excitatory signal. This provides a mechanism to explain the enhancement by caffeine on human cognition ([@B3]), which is not readily observed in adult rodents (e.g., [@B15]; [@B21]; [@B26]; [@B41]; reviewed in [@B13]), where caffeine intake mostly normalizes rather than bolsters learning and memory performance. Thus, these findings provide the first neurophysiological description of the impact of caffeine on excitatory synaptic transmission in the human temporal cortex, providing adequate ground for the effects of caffeine in normal consumption amounts on cognition in humans.
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